Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Amylyx Pharmaceuticals reported its Q3 2024 financial results, highlighting key developments and financial metrics. The company announced positive topline data from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, showing improvements in pancreatic function and other disease measures. Amylyx plans to initiate a Phase 3 program for avexitide in post-bariatric hypoglycemia by Q1 2025. The company holds $234.4 million in cash and securities, sufficient to fund operations into 2026. Financial results showed a net product revenue of $0.4 million, a net loss of $72.7 million, and significant decreases in R&D and SG&A expenses compared to Q3 2023. The company is also progressing with other clinical programs, including the Phase 1 LUMINA trial for AMX0114 in ALS, expected to start in late 2024 or early 2025.
Amylyx Pharmaceuticals ha riportato i risultati finanziari del terzo trimestre 2024, evidenziando sviluppi chiave e metriche finanziarie. L'azienda ha annunciato dati positivi dal trial di Fase 2 HELIOS per AMX0035 nella sindrome di Wolfram, mostrando miglioramenti nella funzione pancreatica e in altre misure della malattia. Amylyx prevede di avviare un programma di Fase 3 per avexitide nell'ipoglicemia post-bariatrica entro il primo trimestre del 2025. L'azienda detiene 234,4 milioni di dollari in contante e titoli, sufficienti per finanziare le operazioni fino al 2026. I risultati finanziari hanno mostrato un fatturato netto da prodotto di 0,4 milioni di dollari, una perdita netta di 72,7 milioni di dollari e significative riduzioni delle spese in R&D e SG&A rispetto al terzo trimestre 2023. L'azienda sta anche proseguendo con altri programmi clinici, incluso il trial di Fase 1 LUMINA per AMX0114 in SLA, previsto per iniziare alla fine del 2024 o all'inizio del 2025.
Amylyx Pharmaceuticals informó sus resultados financieros del tercer trimestre de 2024, destacando desarrollos clave y métricas financieras. La compañía anunció datos positivos de su ensayo de Fase 2 HELIOS de AMX0035 en el síndrome de Wolfram, mostrando mejoras en la función pancreática y otras medidas de la enfermedad. Amylyx planea iniciar un programa de Fase 3 para avexitide en hipoglucemia post-bariátrica para el primer trimestre de 2025. La empresa tiene 234.4 millones de dólares en efectivo y valores, suficientes para financiar operaciones hasta 2026. Los resultados financieros mostraron ingresos netos de productos de 0.4 millones de dólares, una pérdida neta de 72.7 millones de dólares y disminuciones significativas en los gastos de I+D y SG&A en comparación con el tercer trimestre de 2023. La compañía también está avanzando con otros programas clínicos, incluido el ensayo LUMINA de Fase 1 para AMX0114 en ELA, que se espera que comience a finales de 2024 o principios de 2025.
에이미룩스 제약회사는 2024년 3분기 재무 결과를 발표하며 주요 개발 사항과 재무 지표를 강조했습니다. 이 회사는 Wolfram 증후군의 AMX0035에 대한 2상 HELIOS 시험에서 긍정적인 topline 데이터를 발표하며 췌장 기능 및 기타 질병 지표의 개선을 보여주었습니다. 에이미룩스는 2025년 1분기까지 비만 수술 후 저혈당증에 대한 avexitide의 3상 프로그램을 시작할 계획입니다. 이 회사는 현금 및 유가 증권으로 2억 3천4백만 달러를 보유하고 있어 2026년까지 운영 자금을 지원할 수 있습니다. 재무 결과는 순 제품 수익 40만 달러, 순 손실 7270만 달러, 및 2023년 3분기 대비 R&D 및 SG&A 비용의 상당한 감소를 보여주었습니다. 이 회사는 또한 2024년 말 또는 2025년 초에 시작될 예정인 ALS의 AMX0114에 대한 1상 LUMINA 시험을 포함하여 다른 임상 프로그램도 진행하고 있습니다.
Amylyx Pharmaceuticals a publié ses résultats financiers pour le troisième trimestre 2024, soulignant des développements clés et des indicateurs financiers. La société a annoncé des données positives de son essai de Phase 2 HELIOS sur AMX0035 dans le syndrome de Wolfram, montrant des améliorations de la fonction pancréatique et d'autres mesures de la maladie. Amylyx prévoit de lancer un programme de Phase 3 pour l'avexitide dans l'hypoglycémie post-bariatrie d'ici le premier trimestre 2025. La société dispose de 234,4 millions de dollars en espèces et en titres, suffisants pour financer ses opérations jusqu'en 2026. Les résultats financiers ont montré des revenus nets de produits de 0,4 million de dollars, une perte nette de 72,7 millions de dollars et des diminutions significatives des dépenses en R&D et SG&A par rapport au troisième trimestre 2023. La société fait également des progrès avec d'autres programmes cliniques, y compris l'essai LUMINA de Phase 1 pour AMX0114 dans la SLA, qui devrait commencer fin 2024 ou début 2025.
Amylyx Pharmaceuticals hat die Finanzzahlen für das dritte Quartal 2024 veröffentlicht und dabei wichtige Entwicklungen sowie Finanzkennzahlen hervorgehoben. Das Unternehmen gab positive topline Daten aus seiner Phase-2-Studie HELIOS zu AMX0035 im Zusammenhang mit dem Wolfram-Syndrom bekannt, die Verbesserungen bei der Bauchspeicheldrüsenfunktion und anderen Krankheitsmessungen zeigten. Amylyx plant, bis zum ersten Quartal 2025 ein Phase-3-Programm für Avexitid bei postbariatrischer Hypoglykämie zu starten. Das Unternehmen verfügt über 234,4 Millionen Dollar in Bargeld und Wertpapieren, was ausreicht, um die Geschäfte bis 2026 zu finanzieren. Die finanziellen Ergebnisse zeigten einen Umsatz aus Produkten von 0,4 Millionen Dollar, einen Nettoverlust von 72,7 Millionen Dollar und signifikante Rückgänge bei den Forschung- und Entwicklungskosten sowie den Vertriebs- und Verwaltungskosten im Vergleich zum dritten Quartal 2023. Das Unternehmen schreitet auch bei anderen klinischen Programmen voran, darunter die Phase-1-Studie LUMINA für AMX0114 bei ALS, die voraussichtlich Ende 2024 oder Anfang 2025 beginnen wird.
- Positive topline data from Phase 2 HELIOS trial for AMX0035 in Wolfram syndrome.
- Phase 3 program for avexitide in PBH set to initiate in Q1 2025.
- Cash runway expected to last into 2026.
- Significant reduction in R&D and SG&A expenses compared to Q3 2023.
- Net loss of $72.7 million for Q3 2024.
- Net product revenue of only $0.4 million.
- Cash position decreased from $309.8 million as of June 30, 2024, to $234.4 million as of September 30, 2024.
Insights
The Q3 results highlight significant financial and operational shifts. With
The pipeline developments present a mixed outlook. The positive Phase 2 HELIOS trial results for AMX0035 in Wolfram syndrome show promise in pancreatic function and glucose management. The acquisition of avexitide, with FDA Breakthrough Therapy and Orphan Drug Designations for PBH, strengthens the late-stage pipeline. However, the AMX0114 program faces regulatory hurdles with the FDA clinical hold, though development continues in Canada. The company's diversification into rare diseases like Wolfram syndrome (~3,000 US patients) and post-bariatric hypoglycemia demonstrates a strategic shift from their previous ALS focus.
- On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025
- Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures at Week 24 and sustained improvement at Weeks 36 and 48
-
Cash, cash equivalents and marketable securities of
$234.4 million
- Management to host conference call and webcast today at 8:00 a.m. Eastern Time
“This quarter, we continued to advance our late-stage pipeline as part of our goal to bring new potential treatments to communities with high unmet needs. We recently reported positive topline data from our Phase 2 HELIOS clinical trial in people living with Wolfram syndrome that show AMX0035 resulted in meaningful improvements across multiple measures of disease progression as well as sustained improvement over time. We plan to engage with the FDA and other stakeholders to inform our Phase 3 program in Wolfram,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “Additionally, we are on track to initiate a Phase 3 program for our lead asset avexitide in post-bariatric hypoglycemia in the first quarter of next year and remain on track to report interim data from our Phase 2b/3 ORION clinical trial of AMX0035 in progressive supranuclear palsy in mid-2025. With cash runway into 2026, we believe we are well positioned to deliver on these milestones as we continue our critical work in neurodegenerative diseases and endocrine conditions.”
Third Quarter and Recent Updates:
-
Announced positive topline data for all 12 participants in the Phase 2 HELIOS clinical trial, a single-site, single-arm, open-label trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with Wolfram syndrome. Wolfram syndrome is a rare, progressive, monogenic disease impacting approximately 3,000 people in the
U.S. HELIOS showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the trial’s primary efficacy endpoint, in contrast to the expected decrease in pancreatic function with disease progression. Similar overall improvements or stabilization were observed across all secondary endpoints, including hemoglobin A1c (HbA1c), time in target glucose range assessed by continuous glucose monitoring (CGM), and visual acuity. The safety profile of AMX0035 in HELIOS was consistent with prior safety data. The Company is engaging with stakeholders and plans to meet with theU.S. Food and Drug Administration (FDA) to inform a Phase 3 program and expects to provide an update in 2025.
- Acquired avexitide, a Phase 3-ready glucagon-like peptide-1 (GLP-1) receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation in hyperinsulinemic hypoglycemia. Avexitide has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in three clinical trials for congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia. In previous Phase 2 and Phase 2b studies in PBH, avexitide showed statistically significant reductions in hypoglycemia events. FDA guidance for industry combined with initial FDA feedback specific to the planned pivotal Phase 3 program of avexitide for PBH suggest that reduction in hypoglycemia events could be an endpoint to support approval following positive results from a pivotal Phase 3 clinical trial.
- Announced publication of data showing encouraging effects of AMX0035 on cerebrospinal fluid (CSF) biomarkers of core Alzheimer’s disease (AD) pathology and neurodegeneration in the peer-reviewed medical journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer’s Association. The exploratory analyses on CSF biomarkers from participants with AD from the Phase 2 PEGASUS clinical trial suggest that treatment with AMX0035 resulted in consistent changes in AD and neurodegeneration CSF biomarkers in participants with a broad range of disease severity. Findings from the exploratory analysis provide preliminary evidence that AMX0035 engages multiple pathological pathways related to neurodegeneration, including tau.
- Presented the planned Phase 1 study design of AMX0114 in people living with amyotrophic lateral sclerosis (ALS) at the 2024 Northeast ALS Consortium Annual Meeting. The Phase 1 LUMINA clinical trial, a multicenter, randomized, placebo-controlled, multiple ascending dose trial, will evaluate the safety and biological activity of AMX0114 in approximately 48 people living with ALS. Four dose levels of AMX0114 or placebo are planned to be examined sequentially starting with 12.5 mg.
-
Received clearance from Health Canada for the Company’s Clinical Trial Application for AMX0114 in people living with ALS. Amylyx plans to begin the LUMINA trial with a starting dose of 12.5 mg in
Canada by the end of 2024 or in early 2025. The Company also submitted an Investigational New Drug application to the FDA for AMX0114. The FDA restricted dosing to an amount that is lower than the Company’s proposed starting dose of 12.5 mg and has requested additional information, which resulted in a clinical hold. Toxicology data from studies showed a greater than 10X safety margin at the starting dose of 12.5 mg based on the no observed adverse effect level (NOAEL) determined by independent toxicology firms. Amylyx is working to address FDA comments and believes the trial can be completed outside of theU.S. if needed. The Company expects early cohort data from LUMINA in 2025.
Upcoming Expected Milestones:
-
The Company plans to initiate the Phase 1 LUMINA clinical trial of AMX0114 in people living with ALS by the end of 2024 or in the beginning of 2025 in
Canada . AMX0114 is an antisense oligonucleotide targeting inhibition of calpain-2, a well-established target in a number of neurological diseases and a protease known to cleave many substrates including neurofilament, tau, and TDP43 proteins. Amylyx expects early cohort data from LUMINA in 2025.
- Amylyx continues to expect initiation of its Phase 3 program for avexitide in PBH in the first quarter of 2025. Topline data are anticipated in 2026.
- Data from an interim analysis of the Phase 2b/3 ORION clinical trial of AMX0035 in progressive supranuclear palsy (PSP) continue to be expected in mid-2025. ORION is an operationally seamless Phase 2b/3 clinical trial. The Phase 2b portion will include approximately 100 people living with PSP. Amylyx plans to conduct an interim analysis in these participants through Week 24 and will use this data to inform a go/no-go decision on the Phase 3 portion of the trial in mid-2025.
Financial Results for the Third Quarter Ended September 30, 2024
Net product revenue: Net product revenue was
Cost of Sales: Cost of sales were
Acquired in-process research and development: Acquired in-process research and development expenses were
R&D Expenses: Research and development expenses were
SG&A Expenses: Selling, general and administrative expenses were
Net Loss: Net loss for the three months ended September 30, 2024, was
Cash Position: Cash, cash equivalents, and marketable securities were
Investor Conference Call Information
Amylyx’ management team will host a conference call today, November 7, 2024, at 8:00 a.m. ET to discuss financial results and provide an update on the business. To access the conference call, please dial +1 (800)-836-8184 (
Available Information
We periodically provide other information for investors on our corporate website, https://amylyx.com, and our investor relations website, https://investors.amylyx.com. This includes press releases and other information about financial performance, information on corporate governance, and details related to our annual meeting of stockholders. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website, in addition to following the Company’s press releases, SEC filings, and public conference calls and webcasts.
About Avexitide
Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 2 clinical studies for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), with
About AMX0035
AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the
About AMX0114
AMX0114 is an investigational antisense oligonucleotide designed to target the gene encoding calpain-2, a key contributor to the axonal (Wallerian) degeneration pathway. Axonal degeneration has been recognized as an important early contributor to the clinical presentation and pathogenesis of ALS and other neurodegenerative diseases. Calpain-2 has been implicated in the pathogenesis of ALS based on findings of elevated levels of calpain-2 and its cleavage products in postmortem ALS tissue, therapeutic benefit of calpain-2 modulation in animal models of ALS, and the role of calpain-2 in cleaving neurofilament, a broadly researched biomarker in ALS. Preclinical studies completed to date have shown that AMX0114 achieves potent, dose-dependent, and durable knockdown of CAPN2 mRNA expression and calpain-2 protein levels in human motor neurons. Moreover, in preclinical efficacy studies, treatment with AMX0114 reduced extracellular neurofilament light chain levels following neurotoxic insult in induced pluripotent stem cell (iPSC)-derived human motor neurons, and improved survival of iPSC-derived human motor neurons harboring ALS-linked, pathogenic TDP-43 mutations.
About Post-Bariatric Hypoglycemia (PBH)
Symptomatic post-bariatric hypoglycemia (PBH) is a condition that affects approximately
About Congenital Hyperinsulinism (HI)
Congenital hyperinsulinism (HI) is a rare disease characterized by hypersecretion of insulin leading to severe, persistent hypoglycemia in infants and young children with limited therapeutic options. Common symptoms of congenital HI include lack of energy, irritability, lethargy, and excessive hunger. Repeated episodes of low blood glucose increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.
About the HELIOS Trial
HELIOS (NCT05676034) is a 12-participant, single-site, single-arm, open-label, proof of biology, Phase 2 trial designed to study the effect of AMX0035 on safety and tolerability, and various measures of endocrinological, neurological, and ophthalmologic function in adult participants living with Wolfram syndrome. Participants in HELIOS receive AMX0035 for up to 96 weeks followed by a four-week safety follow-up. Primary and secondary outcomes are assessed at Week 24 and at longer-term time points.
In September 2022, researchers from Washington University School of Medicine in
About Wolfram Syndrome
Wolfram syndrome is a rare, monogenic neurodegenerative disease characterized by childhood-onset diabetes, optic nerve atrophy, and neurodegeneration. Common manifestations of Wolfram syndrome include diabetes mellitus and diabetes insipidus, gradual vision loss leading to blindness, hearing loss, neurogenic bladder, difficulties with balance and coordination, and difficulty breathing. Genetic and experimental evidence suggests that endoplasmic reticulum (ER) dysfunction is a critical pathogenic component of Wolfram syndrome. The prognosis of Wolfram syndrome is poor, and many people with the disease die prematurely with severe neurological disabilities.
About the ORION Trial
The ORION trial (NCT06122662) is a global, randomized, double-blind, placebo-controlled Phase 2b/3 clinical trial designed to assess the efficacy, safety, and tolerability of AMX0035 compared to placebo in people living with progressive supranuclear palsy (PSP). ORION was designed and planned in collaboration with key global academic leaders, people living with PSP and their caregivers, and industry advocacy organizations.
About PSP
Progressive supranuclear palsy (PSP) is a sporadic, rare, and fatal neurodegenerative disorder that affects movement, gait, balance, eye movements, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis. PSP typically begins in late-middle age and rapidly progresses over time. The disease affects approximately seven in 100,000 people worldwide, and there are currently no disease-modifying therapies approved for the treatment of PSP.
PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy. Similar to other neurodegenerative diseases, pathophysiologic changes underlying PSP are multifactorial, with several genetic and environmental factors likely contributing to tau dysfunction and aggregation.
Multiple pathways, including genetic mutations, endoplasmic reticulum (ER) stress, and the activation of unfolded protein response, mitochondrial dysfunction, and neuroinflammation have been implicated as contributors to tau dysfunction and aggregation.
About ALS
Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death. More than
About Amylyx Pharmaceuticals
Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in
Forward-Looking Statements
Statements contained in this press release and related comments in our earnings conference call regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the potential of avexitide as a treatment for PBH and HI; expectations regarding the timing of initiation of a Phase 3 trial of avexitide in PBH; the potential of AMX0035 (sodium phenylbutyrate and taurursodiol) as a treatment for Wolfram syndrome and PSP or other neurodegenerative diseases; expectations regarding the timing of the announcement of results from the Company’s Phase 3 ORION trial of AMX0035 for the treatment of PSP; planned discussions with regulatory authorities related to AMX0035 for the treatment of Wolfram syndrome; the potential for AMX0114 as a treatment for ALS and the planned initiation of a trial evaluating AMX0114 in ALS, including potential expansion into the
AMYLYX PHARMACEUTICALS, INC. |
|
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
|||||||
UNAUDITED |
|
|||||||
(in thousands) |
|
|||||||
|
|
|||||||
|
|
September 30,
|
|
|
December 31,
|
|
||
Assets |
|
|
|
|
|
|
||
Cash, cash equivalents and short-term investments |
|
$ |
234,395 |
|
|
$ |
371,362 |
|
Accounts receivable, net |
|
|
1,731 |
|
|
|
40,050 |
|
Inventories |
|
|
— |
|
|
|
83,280 |
|
Prepaid expenses and other current assets |
|
|
9,137 |
|
|
|
14,931 |
|
Other assets |
|
|
5,450 |
|
|
|
7,831 |
|
Total assets |
|
$ |
250,713 |
|
|
$ |
517,454 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
51,943 |
|
|
$ |
79,785 |
|
Other liabilities |
|
|
2,567 |
|
|
|
4,237 |
|
Total liabilities |
|
|
54,510 |
|
|
|
84,022 |
|
Stockholders’ equity |
|
|
196,203 |
|
|
|
433,432 |
|
Total liabilities and stockholders' equity |
|
$ |
250,713 |
|
|
$ |
517,454 |
|
AMYLYX PHARMACEUTICALS, INC. |
|
|||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|
|||||||||||||||
UNAUDITED |
|
|||||||||||||||
(in thousands, except share and per share data) |
|
|||||||||||||||
|
|
|||||||||||||||
|
|
Three Months Ended
|
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Product revenue, net |
|
$ |
416 |
|
|
$ |
102,693 |
|
|
$ |
88,036 |
|
|
$ |
272,337 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
— |
|
|
|
5,218 |
|
|
|
5,953 |
|
|
|
16,081 |
|
Cost of sales - inventory impairment and loss on firm purchase commitments |
|
|
809 |
|
|
|
— |
|
|
|
118,680 |
|
|
|
— |
|
Acquired in-process research and development |
|
|
36,203 |
|
|
|
— |
|
|
|
36,203 |
|
|
|
— |
|
Research and development |
|
|
21,237 |
|
|
|
30,037 |
|
|
|
81,192 |
|
|
|
83,273 |
|
Selling, general and administrative |
|
|
17,828 |
|
|
|
48,718 |
|
|
|
97,234 |
|
|
|
136,115 |
|
Restructuring expenses |
|
|
— |
|
|
|
— |
|
|
|
22,851 |
|
|
|
— |
|
Total operating expenses |
|
|
76,077 |
|
|
|
83,973 |
|
|
|
362,113 |
|
|
|
235,469 |
|
(Loss) income from operations |
|
|
(75,661 |
) |
|
|
18,720 |
|
|
|
(274,077 |
) |
|
|
36,868 |
|
Other income, net |
|
|
2,957 |
|
|
|
3,691 |
|
|
|
10,122 |
|
|
|
10,953 |
|
(Loss) income before income taxes |
|
|
(72,704 |
) |
|
|
22,411 |
|
|
|
(263,955 |
) |
|
|
47,821 |
|
Provision for income taxes |
|
|
— |
|
|
|
1,518 |
|
|
|
242 |
|
|
|
3,281 |
|
Net (loss) income |
|
$ |
(72,704 |
) |
|
$ |
20,893 |
|
|
$ |
(264,197 |
) |
|
$ |
44,540 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net (loss) income per share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
(1.07 |
) |
|
$ |
0.31 |
|
|
$ |
(3.89 |
) |
|
$ |
0.66 |
|
Diluted |
|
$ |
(1.07 |
) |
|
$ |
0.30 |
|
|
$ |
(3.89 |
) |
|
$ |
0.63 |
|
Weighted-average shares used in computing net (loss) income per share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
68,091,446 |
|
|
|
67,414,669 |
|
|
|
67,990,613 |
|
|
|
67,124,407 |
|
Diluted |
|
|
68,091,446 |
|
|
|
69,748,547 |
|
|
|
67,990,613 |
|
|
|
70,143,659 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107293249/en/
Media
Amylyx Media Team
+1 (857) 799-7274
amylyxmediateam@amylyx.com
Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com
Source: Amylyx Pharmaceuticals, Inc.
FAQ
What were Amylyx Pharmaceuticals' financial results for Q3 2024?
What is the cash position of Amylyx Pharmaceuticals as of Q3 2024?
When is Amylyx Pharmaceuticals planning to initiate the Phase 3 program for avexitide?
What are the highlights from the Phase 2 HELIOS trial of AMX0035?
What are the upcoming milestones for Amylyx Pharmaceuticals?
